Grifols S.A. is a global healthcare company that specializes in the development, production, and marketing of plasma-derived therapies and other innovative healthcare solutions. The company focuses on treating a variety of health conditions, including immune deficiencies, hemophilia, and other chronic diseases, by harnessing the therapeutic potential of human plasma. Grifols is also involved in the manufacture of diagnostic tools and systems, contributing to improved patient care and disease management. With a commitment to research and development, Grifols aims to advance the field of medicine through cutting-edge technologies and a robust portfolio of life-saving products.
NEW YORK, NY - (NewMediaWire) - August 31, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
NEW YORK, NY - (NewMediaWire) - August 29, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
NEW YORK, NY - (NewMediaWire) - August 27, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
Brookfield Asset Management is reportedly pursuing €9.5 billion in debt financing for a potential take-private deal for Grifols. The deal could lead to major financial restructuring, impacting bondholders and shareholders amid scrutiny of Grifols' high debt levels and credit downgrades.
NEW YORK, NY - (NewMediaWire) - August 02, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
NEW YORK, NY - (NewMediaWire) - July 31, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
NEW YORK, NY - (NewMediaWire) - July 30, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).
